Abstract:Background: The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. Purpose: This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Methods: Cell Counting Kit -8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Delta psi m) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. Results: CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin -like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p -ATM) and phosphorylated H2A histone family member X (gamma-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and gamma-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick -end labeling (TUNEL) level. Conclusion: This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage -dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM) -dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done.

Comprehensive Assessment of Cucurbitacin E Related Hepatotoxicity and Drug-Drug Interactions Involving CYP3A and P-glycoprotein.

Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells

In Vitro and in Vivo Evaluation of Cucurbitacin E on Rat Hepatic CYP2C11 Expression and Activity Using LC-MS/MS

Growth inhibitory effect of Cucurbitacin E on breast cancer cells.

Inhibitory Effect of Cucurbitacin E on the Proliferation of Breast Cancer Cells and Its Mechanism

Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics

In Vitro and in Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product from Cucumber

Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways

Simultaneous Determination of Cucurbitacin B and Cucurbitacin E in Rat Plasma by UHPLC-MS/MS: A Pharmacokinetics Study after Oral Administration of Cucurbitacin Tablets.

Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways

In Vitro and in Situ Evaluation of Herb–drug Interactions During Intestinal Metabolism and Absorption of Baicalein

Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization

Metabolic fate of the natural anticancer agent cucurbitacin B: an LC-MS/MS-enabled profiling of its major phase I and II conjugates in vivo

Investigation of apoptotic effects of Cucurbitacin D, I, and E mediated by Bax/Bcl‐xL, caspase‐3/9, and oxidative stress modulators in HepG2 cell line

Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway.

Cucurbitacin B Suppresses Hepatocellular Carcinoma Progression Through Inducing DNA Damage-Dependent Cell Cycle Arrest.

Cucurbitacin B Inhibits 12-O-tetradecanoylphorbol 13-Acetate-induced Invasion and Migration of Human Hepatoma Cells Through Inactivating Mitogen-Activated Protein Kinase and Pi3k/Akt Signal Transduction Pathways

In vitro study on the effect of cornin on the activity of cytochrome P450 enzymes

Synergistic Effect of Cucurbitacin B in Combination with Curcumin Via Enhancing Apoptosis Induction and Reversing Multidrug Resistance in Human Hepatoma Cells.

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Inhibition of CYP3A4 and CYP2C9 by Podophyllotoxin: Implication for Clinical Drug–drug Interactions